IP Library Granted Patent US 8,019,557
Granted Patent B2
US 8,019,557 · App. 12/632,221 · Granted Sep 13, 2011

Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same

Assignee: The Trustees of the University of Pennsylvania
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,019,557
App. No.
12/632,221
Granted
Sep 13, 2011
Kind
B2
Abstract

Method of identifying compounds that modulate intermolecular interactions between a target protein and a modifier are disclosed. Pharmaceutical composition comprising compounds that inhibit intermolecular interactions between a target protein and a modifier are disclosed. Methods of treating individual suffering from inflammatory conditions, undesirable immune responses, immunological conditions and bacterial infections are disclosed.

Claims (10)

1. A method of identifying a compound that is an allosteric modulator of an intermolecular interaction between a β-lactamase and a substrate at a functionally critical site of said β-lactamase which comprises:

a) identifying an allosteric cavity on the β-lactamase that is within about 15 to 20 angstroms of said functionally critical site on the β-lactamase;

b) calculating the dimensions of said cavity and mapping the chemical and/or electrostatic properties of said cavity;

c) utilizing the calculated dimensions, chemical and/or electrostatic properties obtained in step b) to identify compounds that contain at least one functional group that can be accommodated by said cavity;

d) testing said compounds in an in vitro assay to detect a compound which modulates the interaction at the functionally critical site between said β-lactamase and said substrate;

thereby identifying said compound that is an allosteric modulator of said intermolecular interaction at said functionally critical site.

2. The method according to claim 1 wherein identifying the allosteric cavity within the structure of β-lactamase in step a) comprises using nuclear magnetic resonance, crystal structure analysis, calorimetric values from thermodynamic studies, or computer modeling.

3. The method according to claim 2 , wherein the allosteric cavity is identified using nuclear magnetic resonance or crystal structure analysis, and further comprises identifying thermal β-factors.

4. The method according to any one of the preceding claims, wherein step c) comprises identifying compounds having at least one functional group that has shape complementarity to said cavity.

5. The method according to claim 4 , wherein step d) comprises assaying said compounds in vitro to identify a compound that inhibits intermolecular interactions between β-lactamase and the substrate.

Assignments (1)
CONFIRMATORY LICENSE Recorded Aug 18, 2016
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039724/0605 →
Continuity (4)
Continuation 09720647
Provisional Application 60091431 · Jul 1, 1998
Provisional Application 60133435 · May 11, 1999
Related Publication 20100151507A1 · Jun 17, 2010